Concinnity Genetics

📍 Glasgow, United Kingdom🗓 Founded 2021👥 8 employees💰 Last funded Nov 2024
Biotechnology Research🌐 concinnitygenetics.com
Website LinkedIn
Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Concinnity Genetics?
Concinnity Genetics has 1 investors on record on gritt.io, 1 mid-stage.
When did Concinnity Genetics last raise funding?
The most recent investment in Concinnity Genetics recorded on gritt.io was in November 2024.
When was Concinnity Genetics founded?
Concinnity Genetics was founded in 2021.
What industry is Concinnity Genetics in?
Concinnity Genetics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Concinnity Genetics based?
Concinnity Genetics is headquartered in Glasgow, United Kingdom.